Urinary Incontinence Therapeutics Market, By Drug Class (Muscarinic Receptor Antagonists (Anticholinergics) (Solifenacin, Fesoterodine, Oxybutynin, Darifenacin, Tolterodine, and Trospium), β₃-Adrenergic Receptor Agonists, (Mirabegron and Vibegron), Combination Therapy, (Mirabegron + Solifenacin), Neurotoxin/Neuromuscular Blocker, (OnabotulinumtoxinA), and Other Late Phase Drugs), By Incontinence Type (Urge/Overactive Bladder (OAB)/Urge Urinary Incontinence (UUI), Stress Urinary Incontinence (SUI), Mixed Urinary Incontinence (SUI + UUI), and Overflow Urinary Incontinence, Functional incontinence, and Other (Neurogenic/Detrusor Overactivity)), By Route of Administration (Oral, Intravesical/bladder instillation, Topical, and Injectable/intradetrusor), By Gender (Male and Female), By Age Group (Adult (19–64 years), Pediatric (≤18 years), and Geriatric (≥65 years)), By Drug Type (Brand and Generic), By End User (Hospitals, Specialty/Urology clinics, Ambulatory surgical centers, Home care/outpatient use, and Long-term care facilities), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)